<img src="https://s3.amazonaws.com/dl.jddonline.com/articleimages/vol18_6_6/Figure-2.jpg" />
<img src="https://s3.amazonaws.com/dl.jddonline.com/articleimages/vol18_6_6/Figure-3.jpg" />
Treatment Success
Treatment success was defined as at least a 2-grade improvement in global severity by EGSS and ‘clear’ or ‘almost clear’. At week 12, 18.8% of patients achieved treatment success with tazarotene 0.045% lotion compared to 10.1% with combined vehicle (P=.148; Figure 4). Tazarotene 0.045% lotion showed a greater treatment success at week 12 when compared with tazarotene 0.1% cream (16.7%), but differences were not significant.
Subject Self-Assessment (SSA)
Tazarotene 0.045% lotion showed a greater numerical treatment success (‘clear’ or ‘almost clear’) at week 12 in terms of SSA when compared with tazarotene 0.1% cream (P=.768). Treatment success was achieved in 38.5% of patients, compared with 35.9% and 24.6% (tazarotene 0.01% cream and combined vehicle [P=.096], respectively).